Market Capitalization – Big Pharma - Milken Institute

More documents

Recommendations

Info

The Changing Healthcare Industry Willingness to Pay Low High “Me too” Paradise Doomsday Low Ability to Innovate Golden High Age Reality PSBF
<strong>Market</strong> <strong>Capitalization</strong> Investing in Biotechnology Preclinical Phase I Phase II Time Phase III NDA Risk Profile Approval & Launch PSBF
Page 2 and 3: Biopharmaceuticals: The Innovation
Page 4 and 5: Market Capitalization - Big Biotech
Page 6 and 7: Big Pharma vs. Big Biotech Market C
Page 8 and 9: U.S. Biotech Industry Summary Reven
Page 10 and 11: Nasdaq Biotech vs. Nasdaq Composite
Page 12 and 13: Mean Approval Time for New Biologic
Page 14 and 15: New Breast Cancer Drug Helps Women
Page 16 and 17: US$ Billions 35 30 25 20 15 10 5 0
Page 18 and 19: Industry R&D Predominately Higher t
Page 20 and 21: Biotech Deals and Amount Raised 199
Page 22 and 23: Total Alliance Numbers and Deal Val
Page 24 and 25: Alliance Deal Activity Top Transact
Page 26 and 27: US$ Billions 400 300 200 100 0 1994
Page 28 and 29: Up to 6.5 years Up to 6 years Up to
Page 30 and 31: Biotech Products have Better U.S. A
Page 32 and 33: Clinical and Total Cost Reductions
Page 34 and 35: Years 20 15 10 5 0 Average Effectiv
Page 36 and 37: Generics’ Share of U.S Prescripti
Page 38 and 39: Medicines in Development For Heart
Page 40 and 41: Medicines in Development For Cancer
Page 43 and 44: Roadblocks in Early Stage Translati
Page 45: Product Roadblocks in Mid- Stage Tr
Page 49 and 50: Year 2001 Private Financings 180 Ov
Page 51 and 52: $ What has Changed Since 2000 Biote
Page 53 and 54: Science Then Now Science all-import
Page 55 and 56: Exits Then Now Exit via IPO Acquisi
Page 57 and 58: New Paradigms 2000 2010 High severi
Page 59 and 60: Amgen IPO Prospectus Alpha Interfer
Page 61 and 62: Between 1900 and 2000, life expecta

Market Capitalization – Big Pharma - Milken Institute

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?